Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a top drug stock to buy, with RBC Capital raising its price target to $149. Crenessity’s strong launch is predicted to continue exceeding Q3 estimates. Analyst consensus rates NBIX as Strong Buy, with a $141.87 median price target, implying a 19.83% upside.

Morgan Stanley’s Sean Laaman gave Neurocrine Biosciences, Inc. (NASDAQ:NBIX) a Buy rating with a $163 price target. The company specializes in neuroscience-focused pharmaceuticals treating various disorders. Products include treatments for Huntington’s disease, tardive dyskinesia, congenital adrenal hyperplasia, and uterine conditions.

While NBIX shows investment potential, some AI stocks offer greater upside with less risk. For a promising undervalued AI stock benefiting from tariffs and onshoring, check out the best short-term AI stock. Explore more stock options that could double in 3 years and hidden AI stocks to buy now.

Read more at Yahoo Finance: What Does Wall Street Think About Neurocrine Biosciences (NBIX)?